^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
01/20/2021
Excerpt:
Mantle Cell Lymphoma: SECOND-LINE AND SUBSEQUENT THERAPY…Useful under Certain Circumstances…Venetoclax ± rituximab
